Skip to search formSkip to main contentSkip to account menu

PAK4/NAMPT Inhibitor KPT-9274

Known as: KCP-9274, KPT-9274 
An orally bioavailable inhibitor of both the serine/threonine kinase P21-activated kinase 4 (PAK4) and the nicotinamide adenine dinucleotide (NAD… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
KPT-9274, an inhibitor of PAK4 and NAMPT, leads to downregulation of mTORC2 in triple negative breast cancer cells.
Triple negative breast cancer (TNBC) is difficult to treat due to lack of druggable targets. We have found that treatment with… 
2019
2019
PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide… 
2019
2019
Kaempferol as a Potential PAK4 Inhibitor in Triple Negative Breast Cancer: Extra Precision Glide Docking and Free Energy Calculation.
BACKGROUND P-21 activating kinase 4 (PAK4) is implicated in poor prognosis of many human tumors, particularly in triple negative… 
2018
2018
Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia
Purpose: p21-activated kinase 4 (PAK4) plays a significant biological and functional role in a number of malignancies, including… 
2018
2018
Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia
Although substantial progress has been made in the treatment of B-cell acute lymphoblastic leukemia (B-ALL), the prognosis of… 
Highly Cited
2017
Highly Cited
2017
A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth
Breast cancer is a heterogeneous disease consisting of several subtypes. Among these subtypes, triple negative breast cancer is… 
2017
2017
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
Dysregulated oncogenic serine/threonine kinases play a pathological role in diverse forms of malignancies, including multiple… 
2017
2017
Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
2017
2017
Abstract LB-308: KPT-9274 inhibits cellular NAD and synergizes with doxorubicin to treat dogs with lymphoma
Nicotinamide adenine dinucleotide (NAD), an essential metabolite and cofactor of several biological processes (e.g. genomic… 
Highly Cited
2016
Highly Cited
2016
Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma
The p21-activated kinase 4 (PAK4) is a key downstream effector of the Rho family GTPases and is found to be overexpressed in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)